Per-patient specificity for PSMA for HCC ranged from 16.2% (95% CI 6.2–32.0) to 100% (95% CI 39.8–100), with a pooled estimate of 60.5% (95% CI 1.2–97.2). This evidence concerns the gene FOLH1 and hepatocellular carcinoma.